These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 28703785)
1. Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside. Pawlowski M; Meuth SG; Duning T Diagnostics (Basel); 2017 Jul; 7(3):. PubMed ID: 28703785 [TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663 [TBL] [Abstract][Full Text] [Related]
3. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW; Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. Bjerke M; Engelborghs S J Alzheimers Dis; 2018; 62(3):1199-1209. PubMed ID: 29562530 [TBL] [Abstract][Full Text] [Related]
5. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
15. From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients. Tsantzali I; Boufidou F; Sideri E; Mavromatos A; Papaioannou MG; Foska A; Tollos I; Paraskevas SG; Bonakis A; Voumvourakis KI; Tsivgoulis G; Kapaki E; Paraskevas GP Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680493 [TBL] [Abstract][Full Text] [Related]
16. Biomarkers for Alzheimer's disease: current status and prospects for the future. Blennow K; Zetterberg H J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512 [TBL] [Abstract][Full Text] [Related]
17. Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Ritter A; Cummings J Front Neurol; 2015; 6():186. PubMed ID: 26379620 [TBL] [Abstract][Full Text] [Related]
18. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O; Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649 [TBL] [Abstract][Full Text] [Related]
19. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. Begcevic I; Tsolaki M; Brinc D; Brown M; Martinez-Morillo E; Lazarou I; Kozori M; Tagaraki F; Nenopoulou S; Gkioka M; Lazarou E; Lim B; Batruch I; Diamandis EP F1000Res; 2018; 7():1012. PubMed ID: 30191060 [No Abstract] [Full Text] [Related]
20. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]